Bioxytran, Inc. (OTCMKTS:BIXT) Sees Large Decline in Short Interest

Bioxytran, Inc. (OTCMKTS:BIXT) was the recipient of a large decline in short interest in the month of January. As of January 15th, there was short interest totalling 10,300 shares, a decline of 86.7% from the December 31st total of 77,600 shares. Based on an average trading volume of 153,100 shares, the short-interest ratio is presently 0.1 days.

Bioxytran Stock Performance

OTCMKTS:BIXT opened at $0.09 on Wednesday. Bioxytran has a one year low of $0.06 and a one year high of $0.15. The business has a fifty day moving average price of $0.09 and a 200-day moving average price of $0.10.

About Bioxytran

Bioxytran, Inc, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.